- Home
- BL vs SUPN Comparison
BL vs SUPN Comparison
Compare BL & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BL | SUPN |
|---|---|---|
| Founded | 2001 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 2.8B |
| IPO Year | 2016 | 2012 |
Fundamental Metrics
Financial Performance| Metric | BL | SUPN |
|---|---|---|
| Price | $47.38 | $48.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | $59.77 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 807.4K | 634.0K |
| Earning Date | 02-10-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.46 | N/A |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $686,706,000.00 | $681,539,000.00 |
| Revenue This Year | $10.38 | $8.16 |
| Revenue Next Year | $8.73 | $23.82 |
| P/E Ratio | $43.89 | ★ N/A |
| Revenue Growth | ★ 7.36 | 4.54 |
| 52 Week Low | $40.82 | $29.16 |
| 52 Week High | $66.25 | $57.65 |
Technical Indicators
Market Signals| Indicator | BL | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 28.54 | 44.83 |
| Support Level | $50.86 | $47.94 |
| Resistance Level | $54.81 | $50.09 |
| Average True Range (ATR) | 2.19 | 1.55 |
| MACD | -0.43 | -0.29 |
| Stochastic Oscillator | 12.41 | 20.39 |
Price Performance
Historical ComparisonAbout BL BlackLine Inc.
BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their critical processes, including financial close & consolidation, intercompany accounting, and invoice-to-cash. The majority of the revenue of the company is earned in the United States.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.